Research Chemical Designation & Liability
Compounds indexed in the MinMaxMuscle archive are strictly for laboratory research and development. They are NOT approved for human consumption. Theoretical dosing data is aggregated from clinical literature and must not be construed as medical instruction. Professional medical consultation is mandatory prior to any research application.
GIP
Metabolic & Weight Loss
Molecular Dossier
- Rank Index: 79
- Status: Research Only
- What does this mean?
- Molecular Structure: MW: 4984.7 Da | 42 AA | CAS: 85409-38-7 | Primary secretion: K-cells, duodenum and jejunum
About GIP
Glucose-dependent insulinotropic polypeptide (GIP) is a 42-amino acid incretin hormone secreted by K-cells in the small intestinal mucosa in response to fat and carbohydrate ingestion. Along with GLP-1, GIP is responsible for the "incretin effect" — the observation that oral glucose triggers a far greater insulin response than equivalent intravenous glucose. The GIP receptor (GIPR) is expressed on pancreatic beta-cells, adipocytes, and bone. At physiological concentrations, GIP potentiates glucose-stimulated insulin secretion and promotes fat storage in adipose tissue. In type 2 diabetes, GIP's insulinotropic action is largely lost (GIP resistance), while GLP-1 effects are better preserved — a key reason early GIP research focused on GLP-1 rather than GIP. The paradigm shifted dramatically with tirzepatide (Mounjaro/Zepbound), a dual GIP/GLP-1 receptor co-agonist that shows superior weight loss (>20% mean body weight) and glycemic control compared to GLP-1 monotherapy. The mechanism is complex: GIPR agonism in the CNS may potentiate GLP-1 satiety signals via complementary hypothalamic circuits; in adipose tissue, GIPR agonism appears to redirect fatty acid partitioning in ways that reduce toxic lipid accumulation in ectopic sites. Native GIP has a half-life of only 2–5 minutes due to DPP-4 cleavage; tirzepatide's synthetic GIP component is a modified GIP(1-42) analogue with extended half-life via fatty acid conjugation. Research interest in selective GIPR agonists and biased GIPR modulators is accelerating.
Clinical Focus
Incretin Hormone — Insulin Potentiation, Fat Storage, Bone Metabolism
Archival Aliases
Glucose-dependent insulinotropic polypeptide, Gastric inhibitory polypeptide, Incretin GIP
Frequently Asked Questions
Why is GIP important for understanding tirzepatide?
Tirzepatide is a dual GIP/GLP-1 receptor co-agonist. The GIP component was initially controversial because GIP alone does not produce weight loss — but in combination with GLP-1R agonism, GIPR activation in the CNS appears to synergistically amplify satiety signals. The superior weight loss of tirzepatide (~20%) versus semaglutide (~15%) is partly attributed to this GIP contribution.
Does GIP cause fat gain?
In isolation, GIPR agonism in adipose tissue promotes fat storage, which historically made GIP an unattractive obesity target. However, tirzepatide's clinical results show net fat loss despite GIPR activation, suggesting the CNS and metabolic effects outweigh peripheral adipose effects at therapeutic doses.
Why is GIP's insulinotropic effect lost in type 2 diabetes but GLP-1's is not?
GIP resistance in type 2 diabetes is a well-documented phenomenon affecting approximately 50–70% of patients. The mechanism involves downregulation and desensitization of GIPR on pancreatic beta-cells, likely caused by chronic hyperglycemia and beta-cell dysfunction. GLP-1R signaling is partially preserved because GLP-1 uses different intracellular pathways that are more resistant to desensitization in the diabetic beta-cell. This differential resistance was the original reason drug development focused on GLP-1R agonists rather than GIP; tirzepatide's success suggests that pharmacological GIPR agonism can overcome this resistance at supratherapeutic doses.
What is the GIP "obesity paradox" and how does tirzepatide resolve it?
The GIP obesity paradox is the observation that GIP promotes fat storage peripherally (a pro-obesity effect) yet tirzepatide — a GIPR/GLP-1R dual agonist — produces greater fat loss than GLP-1R monotherapy. The resolution appears to be context-dependent receptor activity: in the CNS (hypothalamus, brainstem), GIPR activation by tirzepatide's modified GIP analogue enhances satiety signaling and reduces energy intake. In adipose tissue, the same receptor activation may actually improve lipid flux efficiency, reducing ectopic fat deposition. The pharmacological GIP component in tirzepatide is also a modified analogue, not native GIP, and may have biased receptor signaling that differs from the native peptide's adipose effects.
Clinical Data Matrix
| Parameter | Clinical Value |
|---|---|
| Molecular Weight | MW: 4984.7 Da | 42 AA | CAS: 85409-38-7 | Primary secretion: K-cells, duodenum and jejunum |
| Primary Pathway | Metabolic & Weight Loss |
| Research Phase | Research Only |
Clinical Pros
- Highly selective receptor modulation
- Documented efficacy in Phase II trials
- Minimal systemic cross-reactivity
Research Limitations
- Limited long-term human data
- Strict storage and reconstitution requirements
- Potential for acute homeostatic feedback loops
Community Discussion
Share your questions and experiences with other researchers in the forum.
Discuss in ForumClinical Reference Nodes
Data Verified: 2026-05-15